Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tianjin CanSino Biotechnology Inc.

www.cansinotech.com

Latest From Tianjin CanSino Biotechnology Inc.

China's New Hong Kong Security Law To Derail Biotech IPOs?

A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.

Financing Hong Kong

Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 

Coronavirus COVID-19 BioPharmaceutical

China Bioventures' Role In Virus Fight Helps Secure $721m In New Funding, Deals

Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.

Deals Financing

China Still Leading Vaccines Race Despite Moderna Data, US 'Warp Speed' Plan?

The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.

Coronavirus COVID-19 China
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Tianjin CanSino Biotechnology Inc.
  • Senior Management
  • Xuefeng Yu, Chmn. & CEO
    Zhu Tao, PhD, EVP & CSO
    Helen Mao, PhD, EVP QA
    Dongxu Qin, PhD, EVP BD
    Shao Zhongqi, PhD, V Vaccines
    Robin Harkness, PhD, VP RD Collaborations
    Ping Hou, VP, Chief Engineer
    Lifeng Xu, VP, Reg.
  • Contact Info
  • Tianjin CanSino Biotechnology Inc.
    Phone: 222 561 6001
    185 South Ave
    TEDA West Dist.
    Tianjin,
    China
UsernamePublicRestriction

Register